Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome.
Vermeulen, Ruud C W, Scholte, Hans R · Psychosomatic medicine · 2004 · DOI
Quick Summary
This study tested whether two types of carnitine supplements—acetylcarnitine, propionylcarnitine, or both together—could help reduce fatigue in ME/CFS patients. Over 24 weeks, about 59–63% of patients taking either supplement alone reported significant improvement in fatigue and concentration, though acetylcarnitine worked better for mental fatigue while propionylcarnitine worked better for general fatigue. Unfortunately, most patients experienced worsening fatigue within 2 weeks after stopping treatment.
Why It Matters
Carnitine metabolism has been hypothesized as abnormal in ME/CFS, making this one of the early targeted supplementation trials for the condition. The differential effects of two carnitine forms on different fatigue types provide mechanistic clues about how metabolism might contribute to ME/CFS symptoms. However, the rapid relapse after treatment cessation suggests any benefit may not be sustained without ongoing therapy.
Observed Findings
59% of acetylcarnitine-treated patients and 63% of propionylcarnitine-treated patients showed considerable clinical improvement, versus only 37% in the combined-treatment group.
Attention and concentration improved across all three groups.
Pain complaints did not decrease in any treatment group.
50–52% of patients in acetylcarnitine and propionylcarnitine groups experienced fatigue worsening 2 weeks after treatment ended.
Inferred Conclusions
Acetylcarnitine and propionylcarnitine show differential therapeutic effects, with acetylcarnitine targeting mental fatigue and propionylcarnitine targeting general fatigue.
Combining both compounds may paradoxically reduce efficacy compared to monotherapy.
The rapid symptom relapse after discontinuation suggests carnitine supplementation may require ongoing administration to sustain benefit.
Carnitine may influence cognitive function (attention/concentration) independently of its fatigue-reducing mechanism.
Remaining Questions
Why does the combined treatment perform worse than either supplement alone, and what is the mechanistic basis for differential effects on mental versus general fatigue?
What This Study Does Not Prove
This study does not prove carnitine supplements cause long-term improvement or are superior to placebo, as the open-label design without blinding cannot exclude placebo effect. The short follow-up period (2 weeks post-treatment) does not establish whether benefits persist with continued use or reflect lasting metabolic correction. Correlation between plasma carnitine levels and improvement in only the acetylcarnitine group suggests the mechanism remains unclear.
Tags
Symptom:Cognitive DysfunctionFatigue
Biomarker:Blood Biomarker
Method Flag:PEM Not DefinedWeak Case DefinitionSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →